New York, United States
Thesis is revolutionizing the world of brain supplements with its personalized approach, positioning itself as the world's first personalized nootropics company. Leveraging the understanding that cognitive needs vary among individuals, Thesis offers potent nootropics tailored to each person's unique brain. With a mission to provide the benefits of stimulants without the unwanted side effects, the company has gained traction as a go-to solution for increased focus, creativity, energy, and memory.
Founded in 2017 and headquartered in the United States, Thesis has recently secured $8.40M in Series A investment on 02 May 2023. The notable investment comes from a consortium including Break Trail Ventures, Unilever Ventures, Alive Israel HealthTech Fund, Redo Ventures, as well as notable figures such as Kevin Love and Kate Bock.
Armed with the backing of neuroscientists from Yale, Penn, and MIT and powered by an extensive data set on nootropic efficacy, Thesis occupies a unique position in the Health Care and Pharmaceutical industries, poised for continued growth and innovation.
